Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen V Scoper

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Advances in Therapy|October 7, 2008
Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacyStephen V Scoper
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|December 8, 2010
Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye diseaseJohn D Sheppard, Stephen V Scoper, Sandeep Samudre
Archives of Ophthalmology (Chicago, Ill. : 1960)|July 15, 2009
Modalities to decrease stromal herpes simplex keratitis reactivation ratesJohn D Sheppard, Michael L Wertheimer, Stephen V Scoper
Journal of Cataract and Refractive Surgery|June 25, 2011
Microbial keratitis trends following refractive surgery: results of the ASCRS infectious keratitis survey and comparisons with prior ASCRS surveys of infectious keratitis following keratorefractive proceduresRenée Solomon, Eric D Donnenfeld, Edward J Holland, et al.
Cornea|July 26, 2013
Long-term Supplementation With n-6 and n-3 PUFAs Improves Moderate-to-Severe Keratoconjunctivitis Sicca: A Randomized Double-Blind Clinical TrialJohn D Sheppard, Ruhi Singh, Andrew J McClellan, et al.
Ophthalmology|June 10, 2008
Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%Martin Kaback, Stephen V Scoper, George Arzeno, et al.
Advances in Therapy|January 1, 2008
Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitisStephen V Scoper, Gregg J Berdy, Steven J Lichtenstein, et al.
Advances in Therapy|March 1, 2008
Ocular distribution, bactericidal activity and settling characteristics of TobraDex ST ophthalmic suspension compared with TobraDex ophthalmic suspensionStephen V Scoper, Alan G Kabat, Geoffrey R Owen, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Advances in Therapy|October 7, 2008
Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacyStephen V Scoper
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|December 8, 2010
Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye diseaseJohn D Sheppard, Stephen V Scoper, Sandeep Samudre
Archives of Ophthalmology (Chicago, Ill. : 1960)|July 15, 2009
Modalities to decrease stromal herpes simplex keratitis reactivation ratesJohn D Sheppard, Michael L Wertheimer, Stephen V Scoper
Journal of Cataract and Refractive Surgery|June 25, 2011
Microbial keratitis trends following refractive surgery: results of the ASCRS infectious keratitis survey and comparisons with prior ASCRS surveys of infectious keratitis following keratorefractive proceduresRenée Solomon, Eric D Donnenfeld, Edward J Holland, et al.
Cornea|July 26, 2013
Long-term Supplementation With n-6 and n-3 PUFAs Improves Moderate-to-Severe Keratoconjunctivitis Sicca: A Randomized Double-Blind Clinical TrialJohn D Sheppard, Ruhi Singh, Andrew J McClellan, et al.
Ophthalmology|June 10, 2008
Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%Martin Kaback, Stephen V Scoper, George Arzeno, et al.
Advances in Therapy|January 1, 2008
Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitisStephen V Scoper, Gregg J Berdy, Steven J Lichtenstein, et al.
Advances in Therapy|March 1, 2008
Ocular distribution, bactericidal activity and settling characteristics of TobraDex ST ophthalmic suspension compared with TobraDex ophthalmic suspensionStephen V Scoper, Alan G Kabat, Geoffrey R Owen, et al.
Pageof 1